Literature DB >> 28134230

[Flavonolignans - compounds not only for liver treatment].

Michał Bijak1.   

Abstract

Flavonolignans are the major bioactive components presented in the Milk thistle (Silybum marianum) standarized extract - silymarin. S. marianum is a medicinal plant, which has been using for thousands of years as a remedy for a variety of ailments. Since the 70s of the last century flavonolignans presented in silymarin have been regarded to the official medicine as substances having an hepatoprotective properties. Structurally, flavonolignans are composed of a flavonoid unit (taxifolin) and a phenylpropane unit (coniferyl alcohol), linked together by an oxeran ring. Many studies which have been conducted in recent years demonstrated that flavonolignans posses a various healthy properties. Flavonolignans modulate of a variety cell-signaling pathways as well as inhibit arachidonic acid metabolism, resulting in the reduction of pro-inflammatory mediators formation. The researches performed in last year's demonstrated that the major flavonolignan - silybin is able to inhibit two blood coagulation factors: thrombin and FXa. Flavonolignans have been also studied as a potential anticancer agents. This review article presents flavonolignans health benefits effects not only for the liver.

Entities:  

Keywords:  Silybum marianum; flavonolignans; milk thistle; silymarin

Mesh:

Substances:

Year:  2017        PMID: 28134230

Source DB:  PubMed          Journal:  Pol Merkur Lekarski        ISSN: 1426-9686


  8 in total

Review 1.  The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions.

Authors:  Abdelhakim Bouyahya; Hamza Mechchate; Loubna Oumeslakht; Ikrame Zeouk; Sara Aboulaghras; Abdelaali Balahbib; Gokhan Zengin; Mohammad Amjad Kamal; Monica Gallo; Domenico Montesano; Nasreddine El Omari
Journal:  Biomolecules       Date:  2022-02-25

Review 2.  Phyto-pharmacological perspective of Silymarin: A potential prophylactic or therapeutic agent for COVID-19, based on its promising immunomodulatory, anti-coagulant and anti-viral property.

Authors:  Partha Palit; Aparna Mukhopadhyay; Debprasad Chattopadhyay
Journal:  Phytother Res       Date:  2021-04-04       Impact factor: 6.388

Review 3.  Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism.

Authors:  Michal Bijak
Journal:  Molecules       Date:  2017-11-10       Impact factor: 4.411

4.  Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets.

Authors:  Michal Bijak; Rafal Szelenberger; Angela Dziedzic; Joanna Saluk-Bijak
Journal:  Molecules       Date:  2018-02-10       Impact factor: 4.927

5.  Silibinin and Naringenin against Bisphenol A-Induced Neurotoxicity in Zebrafish Model-Potential Flavonoid Molecules for New Drug Design, Development, and Therapy for Neurological Disorders.

Authors:  Geethanjali Thayumanavan; Srikanth Jeyabalan; Shivkanya Fuloria; Mahendran Sekar; Monica Ravi; Logesh Kumar Selvaraj; Logeshwari Bala; Kumarappan Chidambaram; Siew Hua Gan; Nur Najihah Izzati Mat Rani; M Yasmin Begum; Vetriselvan Subramaniyan; Kathiresan V Sathasivam; Dhanalekshmi U Meenakshi; Neeraj Kumar Fuloria
Journal:  Molecules       Date:  2022-04-15       Impact factor: 4.927

6.  Evaluation of the Cytotoxicity and Genotoxicity of Flavonolignans in Different Cellular Models.

Authors:  Michal Bijak; Ewelina Synowiec; Przemyslaw Sitarek; Tomasz Sliwiński; Joanna Saluk-Bijak
Journal:  Nutrients       Date:  2017-12-14       Impact factor: 6.706

7.  Flavonolignans Inhibit IL1-β-Induced Cross-Talk between Blood Platelets and Leukocytes.

Authors:  Michal Bijak; Angela Dziedzic; Ewelina Synowiec; Tomasz Sliwinski; Joanna Saluk-Bijak
Journal:  Nutrients       Date:  2017-09-15       Impact factor: 6.706

8.  Effects of Taxifolin on Osteoclastogenesis in vitro and in vivo.

Authors:  Cong Cai; Changyu Liu; Liming Zhao; Hui Liu; Weijin Li; Hanfeng Guan; Libo Zhao; Jun Xiao
Journal:  Front Pharmacol       Date:  2018-11-12       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.